Mirvaso Gel (Brimonidine 0.33%)

Mirvaso is the new FDA approved treatment from Galderma that was previously known as Sansrosa, CD07805/47 and Col-118. Mirvaso is the only topical treatment officially approved for the relief of the red face of rosacea. Mirvaso is Brimonidine Topical Gel 0.33% and is available in 30g and 45g tubes, on prescription only. It is used once per day and can last as long as 12 hours.

See below for Mirvaso User Reviews, news and updates

Recent Rosacea Blog Posts

Mirvaso Ingredients

The just approved Mirvaso is a milestone in the long development and approval process. Rosacea sufferers have watched this drug since as early as 2004 when patents started emerging. Now that Mirvaso has been officially approved by the FDA more information about the final formulation has emerged. From the Mirvaso Prescribing Information we can see […]

Continue Reading

Mirvaso – Frequently Asked Questions

Surprise news today that Mirvaso, the product formerly known as Sansrosa, CD07805/47 and Col-118 has been granted approval by the FDA. Here are some of the things we already know about Mirvaso ; The prescription gel will be 0.33% brimonidine (this means each gram of the gel contains 5mg of birmonidine tartrate, which is the […]

Continue Reading

Mirvaso (Sansrosa, Brimonidine) Approved for Rosacea Redness

News today that Galderma has succeeded in gaining FDA Approval for Mirvaso – the brand name chosen for the product that during development was known as Sansrosa, CD07805/47 and Col-118. The Brimonidine Tartrate 0.33% Topical Gel is expected to be available as soon as next month. Great news that approval has been granted after so […]

Continue Reading

Sansrosa looks to be marketed as Mirvaso

Thanks to a post from Barbara, we have learnt that a member of a German support forum for rosacea, that Galderma may be planning to market Sansrosa as Mirvaso. It is pretty brief but here is what we know so far. Re: New form of therapy! by Mary »Wednesday 27 July 2013, 08:56 Hello, I […]

Continue Reading

Some news today from the Phase 2B Sansrosa Trials; Galderma is now confirming that during the 8 week trial, participants did not suffer from tachyphylaxis or rebound. This means that if you stop and start sanrosa or continue to use it for an extended period you likely won’t suffer from a rebound effect or from […]

Continue Reading



Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.